Related Experiment Video
Updated: Jul 2, 2026

An Advanced Murine Model for Nonalcoholic Steatohepatitis in Association with Type 2 Diabetes
Published on: April 26, 2019
Metabolic syndrome as a risk factor for nonalcoholic fatty liver disease
Chung-Huang Tsai1, Tsai-Chung Li, Cheng-Chieh Lin
1Department of Family Medicine, Cheng Ching Hospital, Taichung, Taiwan. 3834@ccgh.com.tw
Background:
Metabolic syndrome has been linked to nonalcoholic fatty liver disease (NAFLD).
Objectives:
The purpose of the current study was to evaluate metabolic syndrome as a risk factor for NAFLD in Taiwanese adults.
Methods:
A cross-sectional study was conducted in which 876 subjects were enrolled. The diagnosis of NAFLD was made by abdominal ultrasonography. The Asia-Pacific modification of the National Cholesterol Education Program (NCEP) Adult Treatment Panel (ATP) III guidelines was used to establish the diagnosis of metabolic syndrome.
Results:
NAFLD was diagnosed in 373 (42.6%) of the study population. Metabolic syndrome was diagnosed in 202 (23.1%) of the study population, and it was independently associated with NAFLD (odds ratio [OR] = 2.37; P < 0.001). Among the components of metabolic syndrome, hypertriglyceridemia (OR = 2.24; P < 0.001), hyperglycemia (OR = 2.23; P = 0.001), increased waist circumference (OR = 1.76; P = 0.013), and the diagnostic components of metabolic syndrome were independently associated with NAFLD.
Conclusion:
Metabolic syndrome and some of its diagnostic components are independent risk factors for NAFLD.
Related Concept Videos
Overview of Lipid Metabolism
Lipolysis: The Breakdown of Lipids:
Lipolysis is the process of breaking down lipids, particularly triglycerides, into glycerol and fatty acids. This process typically occurs in the adipose tissue and is triggered by various hormones, including glucagon and...
Type II Diabetes I: Introduction
Overview of Carbohydrate Metabolism
Glucose transport into cells is facilitated by a family of transport proteins called GLUT (Glucose Transporters). GLUT4 is the primary glucose transporter for insulin-stimulated glucose...
Obesity
Cirrhosis I: Introduction
Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion

